GlaxoSmithKline Pakistan (KAR:GLAXO) Cyclically Adjusted FCF per Share: ₨7.23 (As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨373.01
GF Value ₨323.95
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Cyclically Adjusted FCF per Share?

GlaxoSmithKline Pakistan KAR:GLAXO +0.75% 93 Cyclically Adjusted FCF per Share is ₨7.23 as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨323.95 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GlaxoSmithKline Pakistan's adjusted free cash flow per share for the three months ended in Mar. 2026 was ₨4.121. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₨7.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlaxoSmithKline Pakistan's average Cyclically Adjusted FCF Growth Rate was 35.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GlaxoSmithKline Pakistan was 10.90% per year. The lowest was -6.90% per year. And the median was 2.00% per year.

As of today (2026-07-11), GlaxoSmithKline Pakistan's current stock price is ₨373.01. GlaxoSmithKline Pakistan's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ₨7.23. GlaxoSmithKline Pakistan's Cyclically Adjusted Price-to-FCF of today is 51.59.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GlaxoSmithKline Pakistan was 83.50. The lowest was 14.23. And the median was 24.65.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GlaxoSmithKline Pakistan's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=373.01/7.23
=51.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GlaxoSmithKline Pakistan was 83.50. The lowest was 14.23. And the median was 24.65.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GlaxoSmithKline Pakistan Cyclically Adjusted FCF per Share Related Terms


GlaxoSmithKline Pakistan Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Cyclically Adjusted FCF per Share Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.75 4.99 5.08 5.44 6.81

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.34 6.29 6.68 6.81 7.23

KAR:GLAXO vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cyclically Adjusted Price-to-FCF falls into.


KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pakistan's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.121/330.2130*330.2130
=4.121

Current CPI (Mar. 2026) = 330.2130.

GlaxoSmithKline Pakistan Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.401 241.018 -1.919
201609 2.849 241.428 3.897
201612 5.164 241.432 7.063
201703 -2.072 243.801 -2.806
201706 0.477 244.955 0.643
201709 2.265 246.819 3.030
201712 0.877 246.524 1.175
201803 -1.537 249.554 -2.034
201806 1.404 251.989 1.840
201809 5.248 252.439 6.865
201812 1.622 251.233 2.132
201903 -5.116 254.202 -6.646
201906 -6.206 256.143 -8.001
201909 8.291 256.759 10.663
201912 6.885 256.974 8.847
202003 -0.431 258.115 -0.551
202006 0.836 257.797 1.071
202009 9.127 260.280 11.579
202012 5.062 260.474 6.417
202103 -3.165 264.877 -3.946
202106 1.657 271.696 2.014
202109 5.271 274.310 6.345
202112 7.798 278.802 9.236
202203 0.246 287.504 0.283
202206 -8.145 296.311 -9.077
202209 3.352 296.808 3.729
202212 -10.172 296.797 -11.317
202303 -7.874 301.836 -8.614
202306 -2.891 305.109 -3.129
202309 7.568 307.789 8.119
202312 3.963 306.746 4.266
202403 -1.927 312.332 -2.037
202406 3.954 314.175 4.156
202409 6.581 315.301 6.892
202412 -1.442 315.605 -1.509
202503 -1.138 319.799 -1.175
202506 10.019 322.561 10.257
202509 6.308 324.800 6.413
202512 3.909 324.054 3.983
202603 4.121 330.213 4.121

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ₨7.23 mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Cyclically Adjusted FCF per Share of ₨7.23 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Cyclically Adjusted FCF per Share too high?
GlaxoSmithKline Pakistan's current Cyclically Adjusted FCF per Share is ₨7.23. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Cyclically Adjusted FCF per Share of ₨7.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Cyclically Adjusted FCF per Share is ₨7.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨323.95, compared to a current price of ₨373.01 — trading 15.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ₨7.23. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Cyclically Adjusted FCF per Share is ₨7.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨373.01 is trading 15.1% above its estimated GF Value™ of ₨323.95. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Cyclically Adjusted FCF per Share: ₨7.23
  • GF Value™: ₨323.95 vs. price of ₨373.01 (15.1% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨373.01
Price
₨323.95
GF Value